OCTREOTIDE INJECTION SOLUTION

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

OCTREOTIDE (OCTREOTIDE ACETATE)

Доступна с:

TEVA CANADA LIMITED

код АТС:

H01CB02

ИНН (Международная Имя):

OCTREOTIDE

дозировка:

200MCG

Фармацевтическая форма:

SOLUTION

состав:

OCTREOTIDE (OCTREOTIDE ACETATE) 200MCG

Администрация маршрут:

INTRAVENOUS

Штук в упаковке:

5ML

Тип рецепта:

Prescription

Терапевтические области:

MISCELLANEOUS THERAPEUTIC AGENTS

Обзор продуктов:

Active ingredient group (AIG) number: 0121548010; AHFS:

Статус Авторизация:

CANCELLED POST MARKET

Дата Авторизация:

2018-06-21

Характеристики продукта

PRODUCT MONOGRAPH
PR
OCTREOTIDE INJECTION
(Octreotide as acetate)
Single Dose Vials (1 mL)
50 µg/mL, 100 µg/mL, 500 µg/mL
Multidose Vials (5 mL)
200 µg/mL
STERILE
SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN
Teva Canada Limited
Date of Preparation:
30 Novopharm Court
March 28, 2014
Toronto, Ontario
Canada M1B 2K9
www.tevacanada.com
Submission Control No.: 172353
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
5
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
...........................................................................................................
9
DRUG INTERACTIONS
.........................................................................................................
14
DOSAGE AND ADMINISTRATION
.....................................................................................
15
OVERDOSAGE
.......................................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 18
STORAGE AND STABILITY
.................................................................................................
19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 19
PART II: SCIENTIFIC INFORMATION
...............................................................................
21
PHARMACEUTICAL INFORMATION
.................................................................................
21
DETAILED PHARMACOLOGY
..........